FDA Guidance Encourages Companies To Include Patient Preferences In Submissions

New draft guidance from the US Food and Drug Administration urges medical device firms to incorporate patient preference information (PPI) in the development and evaluation of their products.

The draft document, “Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle,” supersedes final guidance the FDA issued in 2016 which the agency published to help sponsors use patient preferences to strengthen their applications